In a new study entitled “Tryptase is involved in the development of early ventilator-induced pulmonary fibrosis in sepsis-induced lung injury,” researchers identified mechanical ventilation as an inducer of pulmonary fibrosis by modulating secretion of pro-fibrotic factors. The study was published in the journal Critical…
In a recent study entitled “Efficient Delivery to Human Lung Fibroblasts (WI-38) of Pirfenidone Incorporated into Liposomes Modified with Truncated Basic Fibroblast Growth Factor and Its Inhibitory Effect on Collagen Synthesis in Idiopathic Pulmonary Fibrosis,” researchers highlighted a promising, novel treatment for idiopathic pulmonary fibrosis that…
In a new study entitled “Telomere dysfunction causes alveolar stem cell failure,” a research team identified that short telomeres in lung stem cells induce stem cell failure, leading to the underlying cause of diseases like pulmonary fibrosis and emphysema. The study was published in the journal…
A new study recently published in the journal The Lancet Respiratory Medicine revealed potential biomarkers for accurately assessing idiopathic pulmonary fibrosis (IPF) disease progression. The study is entitled “Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE…
Lung transplantation is one option for patients with pulmonary fibrosis, however, according to a recent study, Americans with public insurance that undergo lung transplantation for conditions such as pulmonary fibrosis have worse long-term outcomes than equivalent United Kingdom patients with public insurance and…
A study recently published in The Journal of Pathology led by researchers at the University of Southern California and the Saban Research Institute at Children’s Hospital Los Angeles revealed the mechanism underlying the multiplication of fibrous tissue cells in the lungs of patients with idiopathic pulmonary…
Orphan Drug Status was recently granted to an experimental compound, AEOL 10150, under development by Aeolus Pharmaceuticals to address the need for novel treatments for idiopathic pulmonary fibrosis. AEOL 10150 is a broad-spectrum catalytic antioxidant thought to neutralize reactive nitrogen and oxygen species and, consequently, reduce inflammation, oxidative stress and subsequent…
Belgian based biotech firm Galapagos, a company that specializes in the discovery and development of molecular medicines with new drug targets, announced that its seven year proprietary investment agreement with Janssen Pharmaceuticals, part of the Johnson & Johnson healthcare brand, has been terminated by mutual agreement between the two…
The Pulmonary Fibrosis Foundation (PFF) recently announced the expansion of the Leanne Storch Support Group Fund, designed to assist PFF in its support group experience with individuals with PF and their families and positively impact the pulmonary fibrosis community. In part through generous funding from Boehringer Ingelheim, the…
The independent, non-profit HealthWell Foundation is launching a new fund dedicated to supporting patients who suffer from pulmonary fibrosis. The main mission of the foundation is to offer financial help to underinsured people in the United States in order to improve their access to life-changing medical treatments.
Get regular updates to your inbox.
